These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22269396)

  • 1. Natalizumab may improve cognition and mood in multiple sclerosis.
    Lang C; Reiss C; Mäurer M
    Eur Neurol; 2012; 67(3):162-6. PubMed ID: 22269396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natalizumab efficacy on cognitive impairment in MS.
    Mattioli F; Stampatori C; Bellomi F; Capra R
    Neurol Sci; 2011 Jan; 31 Suppl 3():321-3. PubMed ID: 20535512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study.
    Flechter S; Vardi J; Finkelstein Y; Pollak L
    Isr Med Assoc J; 2007 Jun; 9(6):457-9. PubMed ID: 17642394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue.
    Huolman S; Hämäläinen P; Vorobyev V; Ruutiainen J; Parkkola R; Laine T; Hämäläinen H
    Mult Scler; 2011 Nov; 17(11):1351-61. PubMed ID: 21846692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of sports climbing and yoga on spasticity, cognitive function, mood and fatigue in patients with multiple sclerosis.
    Velikonja O; Curić K; Ozura A; Jazbec SS
    Clin Neurol Neurosurg; 2010 Sep; 112(7):597-601. PubMed ID: 20371148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective decline in information processing in subgroups of multiple sclerosis: an 8-year longitudinal study.
    Bergendal G; Fredrikson S; Almkvist O
    Eur Neurol; 2007; 57(4):193-202. PubMed ID: 17272938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term cognitive training improves mental efficiency and mood in patients with multiple sclerosis.
    Brenk A; Laun K; Haase CG
    Eur Neurol; 2008; 60(6):304-9. PubMed ID: 18824859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Audio Recorded Cognitive Screen (ARCS) in patients with multiple sclerosis: a practical tool for multiple sclerosis clinics.
    Lechner-Scott J; Kerr T; Spencer B; Agland S; Lydon A; Schofield PW
    Mult Scler; 2010 Sep; 16(9):1126-33. PubMed ID: 20621944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cognitive impact of mitoxantrone and methylprednisolone in multiple sclerosis: an open label study].
    Zéphir H; de Sèze J; Dujardin K; Dubois G; Cabaret M; Bouillaguet S; Ferriby D; Stojkovic T; Vermersch P
    Rev Neurol (Paris); 2008 Jan; 164(1):47-52. PubMed ID: 18342057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic indications in symptomatic cognitive and psychopathological disorders in multiple sclerosis].
    Lebrun C
    Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):1085-90. PubMed ID: 11787341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks.
    Morrow SA; O'Connor PW; Polman CH; Goodman AD; Kappos L; Lublin FD; Rudick RA; Jurgensen S; Paes D; Forrestal F; Benedict RH
    Mult Scler; 2010 Nov; 16(11):1385-92. PubMed ID: 20739335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive functioning in children and adolescents with multiple sclerosis.
    MacAllister WS; Belman AL; Milazzo M; Weisbrot DM; Christodoulou C; Scherl WF; Preston TE; Cianciulli C; Krupp LB
    Neurology; 2005 Apr; 64(8):1422-5. PubMed ID: 15851734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up.
    Amato MP; Goretti B; Ghezzi A; Lori S; Zipoli V; Moiola L; Falautano M; De Caro MF; Viterbo R; Patti F; Vecchio R; Pozzilli C; Bianchi V; Roscio M; Martinelli V; Comi G; Portaccio E; Trojano M;
    Neurology; 2010 Sep; 75(13):1134-40. PubMed ID: 20876467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perceived cognitive dysfunction and observed neuropsychological performance: longitudinal relation in persons with multiple sclerosis.
    Christodoulou C; Melville P; Scherl WF; Morgan T; MacAllister WS; Canfora DM; Berry SA; Krupp LB
    J Int Neuropsychol Soc; 2005 Sep; 11(5):614-9. PubMed ID: 16212689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological markers of optimal response to natalizumab in multiple sclerosis.
    Villar LM; García-Sánchez MI; Costa-Frossard L; Espiño M; Roldán E; Páramo D; Lucas M; Izquierdo G; Álvarez-Cermeño JC
    Arch Neurol; 2012 Feb; 69(2):191-7. PubMed ID: 22332187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cognitive burden of multiple sclerosis in children.
    Banwell BL; Anderson PE
    Neurology; 2005 Mar; 64(5):891-4. PubMed ID: 15753431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis.
    Phillips JT; Giovannoni G; Lublin FD; O'Connor PW; Polman CH; Willoughby E; Aschenbach W; Pace A; Hyde R; Munschauer FE
    Mult Scler; 2011 Aug; 17(8):970-9. PubMed ID: 21421809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypereosinophilia in patients with multiple sclerosis treated with natalizumab.
    Abbas M; Lalive PH; Chofflon M; Simon HU; Chizzolini C; Ribi C
    Neurology; 2011 Oct; 77(16):1561-4. PubMed ID: 21975205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early cognitive impairment in multiple sclerosis predicts disability outcome several years later.
    Deloire M; Ruet A; Hamel D; Bonnet M; Brochet B
    Mult Scler; 2010 May; 16(5):581-7. PubMed ID: 20194578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.